PatientsVille.com Logo

PatientsVille

Quadramet Side Effects

Common Quadramet Side Effects


The most commonly reported Quadramet side effects (click to view or check a box to report):

Pain (15)
Thrombocytopenia (13)
Condition Aggravated (12)
Disease Progression (12)
Nausea (9)
Back Pain (8)
Blood Creatinine Increased (7)
Malignant Neoplasm Progression (7)
Haemoglobin Decreased (7)
Arthralgia (6)
Atrial Fibrillation (6)
Haematuria (6)
Dyspnoea (6)
Anorexia (5)
Acute Pulmonary Oedema (5)
Pain In Extremity (5)
Pancytopenia (5)
Platelet Count Decreased (5)
Anxiety (5)
Cardiac Failure Congestive (4)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Quadramet Side Effects Reported to FDA

The following Quadramet reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Quadramet on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Cardiac Arrest
This is a report of a 58-year-old male patient (weight: NA) from US, suffering from the following symptoms/conditions: prostate cancer, who was treated with Quadramet (dosage: (124 Mci (124 Mci), start time: Jan 18, 2012), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:
  • Cardiac Arrest
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Quadramet treatment in male patients, resulting in cardiac arrest side effect.

Platelet Count Decreased, Neutrophil Count Decreased
This report suggests a potential Quadramet Platelet Count Decreased, Neutrophil Count Decreased side effect(s) that can have serious consequences. A 66-year-old male patient (weight: NA) from US was diagnosed with the following symptoms/conditions: prostate cancer and used Quadramet (dosage: NA) starting Dec 19, 2012. Soon after starting Quadramet the patient began experiencing various side effects, including:
  • Platelet Count Decreased
  • Neutrophil Count Decreased
Drugs used concurrently: NA. Although Quadramet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as platelet count decreased, may still occur.

Thrombocytopenia, Prostate Cancer
This Thrombocytopenia, Prostate Cancer problem was reported by a health professional from AU. A 64-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: prostate cancer. On NS this consumer started treatment with Quadramet (dosage: 1.5 Gy X2, Intravenous (not Otherwise Specified)). The following drugs were being taken at the same time: NA. When commencing Quadramet, the patient experienced the following unwanted symptoms/side effects:
  • Thrombocytopenia
  • Prostate Cancer
Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as thrombocytopenia, may become evident only after a product is in use by the general population.

Thrombocytopenia, Prostate Cancer
This is a report of a 71-year-old male patient (weight: NA) from AU. The patient developed the following symptoms/conditions: prostate cancer and was treated with Quadramet (dosage: 1.5 Gy X 2 , Intravenous (not Otherwise Specified)) starting NS. Concurrently used drugs: NA.Soon after that, the consumer experienced the following side effects:
  • Thrombocytopenia
  • Prostate Cancer
This opens a possibility that Quadramet treatment could cause the above reactions, including thrombocytopenia, and some male subjects may be more susceptible.


Thrombocytopenia
A 69-year-old male patient (weight: NA) from US with the following symptoms/conditions: prostate cancer started Quadramet treatment (dosage: NA) on NS. Soon after starting Quadramet treatment, the subject experienced various side effects, including:
  • Thrombocytopenia
Concurrently used drugs: NA. This finding indicates that some male patients could be more vulnerable to Quadramet.

Pancytopenia, Neoplasm Progression, Bone Sarcoma
A 19-year-old female patient from (weight: NA) experienced symptoms, such as: bone sarcoma and was treated with Quadramet(dosage: 37 To 51.8 Mbq/kg (1.0-1.4 Mci/kg)). The treatment was initiated on NS. After that a consumer reported the following side effect(s):
  • Pancytopenia
  • Neoplasm Progression
  • Bone Sarcoma
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Quadramet efficacy:
  • 18f-fdg (fludeoxyglucose)
  • Contrast Media (contrast Media)


Pancytopenia, Bone Sarcoma, Neoplasm Progression
In this report, Quadramet was administered for the following condition: bone sarcoma.A 14-year-old female consumer from (weight: NA) started Quadramet treatment (dosage: 37 To 51.8 Mbq/kg (1.0-1.4 Mci/kg)) on NS.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Pancytopenia
  • Bone Sarcoma
  • Neoplasm Progression
A possible interaction with other drugs could have contributed to this reaction:
  • Contrast Media (contrast Media)
  • 18f-fdg (fludeoxyglucose (18f))
Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Quadramet treatment could be related to the listed above side effect(s).

Bone Sarcoma, Disease Progression, Pancytopenia
This is a report of the following Quadramet side effect(s):
  • Bone Sarcoma
  • Disease Progression
  • Pancytopenia
A 17-year-old male patient from (weight: NA) presented with the following condition: bone sarcoma and received a treatment with Quadramet (dosage: 37 To 51.8 Mbq/kg (1.0-1.4 Mci/kg)) starting: NS.The following concurrently used drugs could have generated interactions:
  • 18f-fdg (fludeoxyglucose (18f))
  • Contrast Media (contrast Media)
This report suggests that a Quadramet treatment could be associated with the listed above side effect(s).

Pleural Effusion, Dyspnoea, Disease Progression, Pancytopenia
This Quadramet report was submitted by a 30-year-old female consumer from (weight: NA). The patient was diagnosed with: NA and Quadramet was administered (dosage: 1.2 Mci/kg, Intravenous) starting: Dec 16, 2005. The consumer developed a set of symptoms:
  • Pleural Effusion
  • Dyspnoea
  • Disease Progression
  • Pancytopenia
Other drugs used simultaneously:
  • 18f-fdg (fludeoxyglucose (18f))
  • Contrast Media (contrast Media)
Those unexpected symptoms could be linked to a Quadramet treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Thrombocytopenia, Renal Failure Acute, Femur Fracture, Malaise, Fatigue, Obstruction
This is a report of a possible correlation between Quadramet use and the following symptoms/side effect(s):
  • Thrombocytopenia
  • Renal Failure Acute
  • Femur Fracture
  • Malaise
  • Fatigue
  • Obstruction
which could contribute to an assessment of Quadramet risk profile.A male consumer from UNITED STATES (weight: NA) was suffering from NA and was treated with Quadramet (dosage: 86.9 Mci) starting NS.Other concurrent medications:
  • Lotrel
  • Vitamin D (400 Iu)
  • Calcium Carbonate (600 Mg)
  • Zometa (4 Mg)
  • Simvastatin
  • Levothroid
  • Aspirin
The patient was hospitalized.

Malignant Neoplasm Progression, Osteosarcoma Metastatic, Pancytopenia
A 18-year-old female patient from UNITED STATES (weight: NA) presented with the following symptoms: bone sarcoma and after a treatment with Quadramet (samarium (153 Gm) Lexidronam) (dosage: 37 To 51.8 Mbq/kg (1.0-1.4 Mci/kg)) experienced the following side effect(s):
  • Malignant Neoplasm Progression
  • Osteosarcoma Metastatic
  • Pancytopenia
The treatment was started on NS. Quadramet (samarium (153 Gm) Lexidronam) was used in combination with the following drugs:
  • 18f-fdg (fludeoxyglucose (18f))
  • Contrast Media(contrast Media)
This report could alert potential Quadramet (samarium (153 Gm) Lexidronam) consumers.

Metastases To Central Nervous System
In this report, a female patient from UNITED STATES (weight: NA) was affected by a possible Quadramet side effect.The patient was diagnosed with NA. After a treatment with Quadramet (dosage: .94 Ml, start date: NS), the patient experienced the following side effect(s):
  • Metastases To Central Nervous System
The following simultaneously used drugs could have led to this reaction:
  • Zometa (4 Mg)
  • Vitamin D2 (3600 Million Iu)
The patient was hospitalized.The findings here stress that side effects should be taken into consideration when evaluating a Quadramet treatment.

Metastases To Central Nervous System
This is a report of a female patient from UNITED STATES (weight: NA), who used Quadramet (dosage: .94 Ml) for a treatment of NA. After starting a treatment on NS, the patient experienced the following side effect(s):
  • Metastases To Central Nervous System
The following drugs could possibly have interacted with the Quadramet treatment
  • Zometa (4 Mg)
  • Vitamin D2 (3600 Million Iu)
The patient was hospitalized.Taken together, these observations suggest that a Quadramet treatment could be related to side effect(s), such as Metastases To Central Nervous System.

Pneumonia
This pneumonia side effect was reported by a pharmacist from UNITED STATES. A 62-year-old female patient (weight:NA) experienced the following symptoms/conditions: palliative care. The patient was prescribed Quadramet (dosage: 50 Mci At A Dose Of 1 Mcg/kg, Intravenous), which was started on Oct 20, 2010. Concurrently used drugs:
  • Docusate (docusate)
  • Zoledronic Acid
When starting to take Quadramet the consumer reported the following symptoms:
  • Pneumonia
These side effects may potentially be related to Quadramet.

Atelectasis, Culture Urine Positive, Diarrhoea, Pyrexia, White Blood Cell Count Decreased
This is a Quadramet side effect report of a 74-year-old male patient (weight:NA) from UNITED STATES, suffering from the following symptoms/conditions: prostate cancer metastatic, who was treated with Quadramet (dosage:1.0 Mci/kg, Intravenous, start time: Aug 27, 2008), combined with:
  • Docetaxel (3.5714 Mg/m2, 1 In 3 Weeks, Intravenous)
  • Zoledronic Acid
  • Lupron
  • Decadron
  • Prednisone Tab
  • Oxycodone Hcl
  • Meloxicam
  • Ibuprofen
, and developed a serious reaction and a atelectasis side effect. The patient presented with:
  • Atelectasis
  • Culture Urine Positive
  • Diarrhoea
  • Pyrexia
  • White Blood Cell Count Decreased
which developed after the beginning of treatment. The patient was hospitalized. This side effect report can indicate a possible existence of increased vulnerability to Quadramet treatment in male patients suffering from prostate cancer metastatic, resulting in atelectasis.

Activities Of Daily Living Impaired, Blood Creatine Increased, Blood Glucose Increased, Carbohydrate Antigen 27.29 Increased, Eosinophil Percentage Increased, Haematocrit Decreased, Haemoglobin Decreased, Lymphocyte Percentage Decreased
This report suggests a potential Quadramet activities of daily living impaired side effect(s) that can have serious consequences. A 57-year-old female patient from UNITED STATES (weight:NA) was diagnosed with the following health condition(s): metastases to bone and used Quadramet (dosage: Intravenous) starting Jan 21, 2010. Soon after starting Quadramet the patient began experiencing various side effects, including:
  • Activities Of Daily Living Impaired
  • Blood Creatine Increased
  • Blood Glucose Increased
  • Carbohydrate Antigen 27.29 Increased
  • Eosinophil Percentage Increased
  • Haematocrit Decreased
  • Haemoglobin Decreased
  • Lymphocyte Percentage Decreased
Drugs used concurrently:
  • Cymbalta (Enteric Coated, 1 Po Bid, Oral)
  • Lorazepam (1 Po Q4h Prn, Oral)
  • Morphine Sulfate (10 Mg/5 Ml; 15 Ml Po Q2-4h Prn, Oral)
  • Morphine Sulfate (Sustained Action, 1 Po O12h, Oral)
  • Ambien Cr, Po Solid Sr (zolpidem Tartrate) (tablets)
  • Azor, Po Solid (amlodipine) (tablets)
  • Caltrate 600+d Plus, Po Solid (calcite D) (tablets)
  • Femara, Po Solid (letrozole) (tablets)
Although Quadramet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as activities of daily living impaired, may still occur.

Blood Creatinine Increased, Blood Glucose Increased, Carbohydrate Antigen 27.29 Increased, Eosinophil Percentage Increased, Haemoglobin Decreased, Lymphocyte Percentage Decreased, Mean Platelet Volume Decreased
This blood creatinine increased problem was reported by a health professional from UNITED STATES. A 57-year-old female patient (weight: NA) was diagnosed with the following medical condition(s): bone pain.On Jan 21, 2010 a consumer started treatment with Quadramet (dosage: Intravenous). The following drugs/medications were being taken at the same time:
  • Cymbalta (Enteric Coated, 1 Po Bid, Oral)
  • Lorazepam (1 Po Q4h Prn, Oral)
  • Morphine Sulfate (10 Mg/5 Ml; 15 Ml Po Q2-4h Prn, Oral)
  • Morphine Sul Hyt (Sustained Action, 1 Po Q12h, Oral)
  • Ambien Cr, Po Solid Sr (zolpidem Tartrate)(tablets)
  • Azor, Po Solid (amlodipine)(tablets)
  • Caltrate 600+d Plus, Po Solid (calcite D)(tablets)
  • Femara, Po Solid (letrozole) (tablets)
When commencing Quadramet, the patient experienced the following unwanted symptoms /side effects:
  • Blood Creatinine Increased
  • Blood Glucose Increased
  • Carbohydrate Antigen 27.29 Increased
  • Eosinophil Percentage Increased
  • Haemoglobin Decreased
  • Lymphocyte Percentage Decreased
  • Mean Platelet Volume Decreased
Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as blood creatinine increased, may become evident only after a product is in use by the general population.

Platelet Count Decreased
This is a Quadramet side effect report of a 56-year-old male patient (weight: NA) from UNITED STATES. The patient developed the following symptoms/conditions: prostate cancer and was treated with Quadramet (dosage: 135 Mci Iv Injection) starting Mar 20, 2008. Concurrently used drugs:
  • ..
  • Zoladex
  • Casodex
Soon after that, the consumer experienced the following of symptoms:
  • Platelet Count Decreased
This opens a possibility that Quadramet could cause platelet count decreased and that some male patients may be more susceptible.

Bloody Discharge, Body Temperature Increased, Disease Progression, Hydronephrosis, Hypotension, Lung Disorder, Lymphadenopathy, Mediastinal Disorder, Neutropenia
A male patient (weight: NA) from UNITED STATES with the following symptoms: NA started Quadramet treatment (dosage: 99.7 Mci) on NS. Soon after starting Quadramet treatment, the consumer experienced several side effects, including:
  • Bloody Discharge
  • Body Temperature Increased
  • Disease Progression
  • Hydronephrosis
  • Hypotension
  • Lung Disorder
  • Lymphadenopathy
  • Mediastinal Disorder
  • Neutropenia
. Concurrently used drugs:
  • Zometa (25.3 Mg)
  • Lupron + Casodex
  • Mitoxantrone + Prednisone
The patient was hospitalized. This finding indicates that some patients can be more vulnerable to developing Quadramet side effects, such as bloody discharge.

No Adverse Event
This no adverse event side effect was reported by a health professional from UNITED STATES. A 65-year-old male patient (weight:NA) experienced the following symptoms/conditions: bone pain.The patient was prescribed Quadramet (dosage: NA), which was started on NS. Concurrently used drugs: NA..When starting to take Quadramet the consumer reported symptoms, such as:
  • No Adverse Event
These side effects may potentially be related to Quadramet.

Asthenia, Dyskinesia, Toxic Encephalopathy
This is a report of a 70-year-old male patient (weight: NA) from UNITED STATES, suffering from the following symptoms/conditions: bone pain, who was treated with Quadramet (dosage: NA, start time: NS), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:
  • Asthenia
  • Dyskinesia
  • Toxic Encephalopathy
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Quadramet treatment in male patients, resulting in asthenia side effect. The patient was hospitalized.

Dehydration, Duodenal Ulcer, Obstruction Gastric, Reflux Oesophagitis, Urinary Tract Infection
This report suggests a potential Quadramet Dehydration, Duodenal Ulcer, Obstruction Gastric, Reflux Oesophagitis, Urinary Tract Infection side effect(s) that can have serious consequences. A male patient (weight: NA) from UNITED STATES was diagnosed with the following symptoms/conditions: NA and used Quadramet (dosage: Received Only One Dose Per The Protocol On 6/27/2007) starting Jun 27, 2007. Soon after starting Quadramet the patient began experiencing various side effects, including:
  • Dehydration
  • Duodenal Ulcer
  • Obstruction Gastric
  • Reflux Oesophagitis
  • Urinary Tract Infection
Drugs used concurrently:
  • Vitamin D (2800 Iu Took 2800 Iu Total For This Course (400iu Per Day) But Started In May Of 2007 With Course 1)
  • Zometa (4 Mg)
The patient was hospitalized. Although Quadramet demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as dehydration, may still occur.

Syncope
This Syncope problem was reported by a consumer or non-health professional from UNITED STATES. A female patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On NS this consumer started treatment with Quadramet (dosage: 69.5 Mg). The following drugs were being taken at the same time:
  • Zometa (4 Mg)
  • Calcium
  • Vitamin D
  • Levothyroxine Sodium
When commencing Quadramet, the patient experienced the following unwanted symptoms/side effects:
  • Syncope
The patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as syncope, may become evident only after a product is in use by the general population.

Agitation, Burning Sensation, Dermatitis Allergic
This is a report of a 57-year-old female patient (weight: NA) from UNITED STATES. The patient developed the following symptoms/conditions: palliative care and was treated with Quadramet (dosage: 176 Gbq) starting Dec 20, 2006. Concurrently used drugs:
  • Morphine
  • Neurontin
  • Nexiam (esomeprazole)
  • Voltaren
  • Serotonin Antagonists
Soon after that, the consumer experienced the following side effects:
  • Agitation
  • Burning Sensation
  • Dermatitis Allergic
The patient was hospitalized. This opens a possibility that Quadramet treatment could cause the above reactions, including agitation, and some female subjects may be more susceptible.

Metastases To Abdominal Cavity, Pain, Thrombocytopenia
A 78-year-old male patient (weight: NA) from UNITED STATES with the following symptoms/conditions: metastases to bone started Quadramet treatment (dosage: 1 Mci/kg, 37mbq/kg 1 Dose, Intravenous) on NS. Soon after starting Quadramet treatment, the subject experienced various side effects, including:
  • Metastases To Abdominal Cavity
  • Pain
  • Thrombocytopenia
Concurrently used drugs:
  • Technetium Tc 99m Methylene Diphosphonate
This finding indicates that some male patients could be more vulnerable to Quadramet.

1 of 4 



Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Quadramet Side Effects

    Did You Have a Quadramet Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Quadramet for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Quadramet Safety Alerts, Active Ingredients, Usage Information

    NDC11994-016
    TypeHUMAN PRESCRIPTION DRUG
    Proprietary NameQuadramet
    NameSamarium SM 153 Lexidronam
    Dosage FormINJECTION, SOLUTION
    RouteINTRAVENOUS
    On market since19970519
    LabelerLantheus Medical Imaging, Inc.
    Active Ingredient(s)SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
    Strength(s)50
    Unit(s)mCi/mL
    Pharma Class

    Quadramet Dosage, Warnings, Usage.

    Side Effects reported to FDA: 80

    Quadramet safety alerts: No

    Reported deaths: 23

    Reported hospitalizations: 69

    Latest Quadramet clinical trials

    Quadramet Reviews

    No reviews, be a first to report a side effect via side effect reporting form